慢性乙型肝炎的HBsAg /抗HBs双阳性患者与HBsAg单阳性患者的长

StephenW

Sci Rep. 2019 Dec 19;9(1):19417. doi: 10.1038/s41598-019-56015-8.
Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B.
Kwak MS1, Chung GE2, Yang JI2, Yim JY2.
Author information

1
    Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea. [email protected].
2
    Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea.

Abstract

The coexistence of HBsAg and anti-HBs has been reported in some chronic hepatitis B patients; however, the long-term outcomes of this serological profile have not been elucidated. We aimed to evaluate the long-term outcomes of HBsAg/anti-HBs double-positive chronic hepatitis B patients. Chronic hepatitis B patients who underwent baseline abdominal ultrasonography and follow-up (HBsAg/anti-HBs assessment and abdominal ultrasonography) at our healthcare center were included. The "coexistence group" included patients positive for both HBsAg and anti-HBs and the "control group" included patients positive for only HBsAg during follow-up. The outcomes were hepatocellular carcinoma (HCC) incidence, HBsAg seroclearance and overall mortality. Kaplan-Meier and Cox proportional hazard regression analyses were performed. Of the 2,341 eligible patients, 166 (7.1%) were in the coexistence group. The total follow-up duration was 5.4 years. The coexistence group had a 3.08-fold higher risk of HCC than the control group [hazard ratio (HR) 3.08, 95% confidence interval(CI) 1.26-7.55, P = 0.014] in multivariate analysis. The coexistence group had more HBsAg seroclearance than the control group (HR 1.43, 95% CI 1.01-2.03, P = 0.046). However, overall mortality did not significantly differ between the 2 groups. The coexistence group is heterogeneous and includes subjects with unfavorable outcomes (incidence of HCC) and favorable outcomes (more HBsAg seroclearance).

PMID:
    31857656
DOI:
    10.1038/s41598-019-56015-8

StephenW

Sci Rep.2019年12月19日; 9（1）：19417。 doi：10.1038 / s41598-019-56015-8。
慢性乙型肝炎的HBsAg /抗HBs双阳性患者与HBsAg单阳性患者的长期预后
Kwak MS1，Chung GE2，Yang JI2，Yim JY2。
作者信息

1个
    韩国首尔首尔国立大学医院医疗系统江南中心医疗研究所研究所内科。 [email protected]。
2
    韩国首尔首尔国立大学医院医疗系统江南中心医疗研究所研究所内科。

抽象

据报道，在一些慢性乙型肝炎患者中，HBsAg和抗-HBs并存。然而，这种血清学特征的长期结果尚未阐明。我们旨在评估HBsAg /抗HBs双阳性慢性乙型肝炎患者的长期预后。包括在我们的医疗中心接受基线腹部超声检查和随访（HBsAg /抗HBs评估以及腹部超声检查）的慢性乙型肝炎患者。 “共存组”包括HBsAg和抗HBs均阳性的患者，“对照组”包括随访期间仅HBsAg阳性的患者。结果是肝细胞癌（HCC）发生率，HBsAg血清清除率和总死亡率。进行了Kaplan-Meier和Cox比例风险回归分析。在2341名合格患者中，有166名（7.1％）在共存组中。总随访时间为5.4年。在多因素分析中，共存组的肝癌风险比对照组高3.08倍[风险比（HR）3.08，95％置信区间（CI）1.26-7.55，P = 0.014]。共存组的HBsAg血清清除率高于对照组（HR 1.43，95％CI 1.01-2.03，P = 0.046）。但是，两组的总死亡率没有显着差异。共存组是异类的，包括预后不良（HCC发生率）和预后良好（HBsAg血清清除率更高）的受试者。

PMID：
    31857656
DOI：
    10.1038 / s41598-019-56015-8

StephenW

https://www.nature.com/articles/s41598-019-56015-8.pdf